Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Hematological Neoplasms: From Diagnosis to Treatment
share announcement

Hematological Neoplasms: From Diagnosis to Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3400

Special Issue Editor

Dr. Atsushi Satake

E-Mail Website
Guest Editor
First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan
Interests: hematology; leukemia; hematological malignancies; transplantation; T lymphocytes

Special Issue Information

Dear Colleagues,

Remarkable progress has been made in the field of hematological oncology. Various immunologic features and genetic abnormalities have been identified for different hematologic malignancies. These findings have contributed to the accurate diagnosis, establishment, and update of the risk classification of various diseases. The assessment of immunological and genetic abnormalities is sometimes useful for selection of the appropriate therapeutic drug and to monitor measurable residual disease during treatment. In addition, targeted therapy has also made substantial progress. The treatment response and prognosis for many diseases that were previously challenging to improve with chemotherapy have since shown improvements. In particular, immune therapy—such as chimeric antigen receptor T-cell therapy and bispecific T-cell engager molecule therapy—has improved the treatment outcome for relapsed or refractory diseases. In this Special Issue, we welcome authors to submit papers on the clinical advancements in hematological oncology regarding diagnosis and treatment.

Dr. Atsushi Satake
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematological malignancy
  • diagnosis
  • risk classification
  • measurable residual disease
  • targeted therapy
  • immune therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 670 KiB  
Article
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations
by Concepción Boqué, Silvia Sánchez-Ramón, Raúl Córdoba, Carol Moreno and Elena Cabezudo
J. Clin. Med. 2023, 12(19), 6356; https://doi.org/10.3390/jcm12196356 - 04 Oct 2023
Viewed by 1411
Abstract
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have [...] Read more.
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected. More than 90% agreed on the need for active immunization against seasonal influenza and H1N1, pneumococcus and Haemophilus influenzae. There was a consensus on the monitoring of IgG levels every 3 months (83%) and the need to have available a clinical protocol for the use of IVIG in the management of SID (94%), to monitor trough IgG levels to determine the correct IVIG dose (86%) and to discontinue IVIG after the recovery of IgG levels after 12 months of follow-up (77%). The findings of the present survey may be useful recommendations for hematologists and immunologists to improve the management of SID in daily practice. Full article
(This article belongs to the Special Issue Hematological Neoplasms: From Diagnosis to Treatment)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research, Other

17 pages, 2420 KiB  
Review
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin
by Tomasz Stein, Tadeusz Robak, Wojciech Biernat and Ewa Robak
J. Clin. Med. 2024, 13(3), 823; https://doi.org/10.3390/jcm13030823 - 31 Jan 2024
Viewed by 731
Abstract
One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been [...] Read more.
One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarises the clinical evidence supporting the current treatment options for these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date. Full article
(This article belongs to the Special Issue Hematological Neoplasms: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

19 pages, 3622 KiB  
Case Report
Possible New Histological Prognostic Index for Large B-Cell Lymphoma
by Hideaki Nitta, Haruko Takizawa, Toru Mitsumori, Hiroko Iizuka-Honma, Yoshihiko Araki, Maki Fujishiro, Shigeki Tomita, Satsuki Kishikawa, Akane Hashizume, Tomohiro Sawada, Mitsuo Okubo, Yasunobu Sekiguchi, Miki Ando and Masaaki Noguchi
J. Clin. Med. 2023, 12(19), 6324; https://doi.org/10.3390/jcm12196324 - 30 Sep 2023
Viewed by 940
Abstract
We conducted a retrospective analysis of GRP94 immunohistochemical (IHC) staining, an ER stress protein, on large B-cell lymphoma (LBCL) cells, intracellular p53, and 15 factors involved in the metabolism of the CHOP regimen: AKR1C3 (HO metabolism), CYP3A4 (CHOP metabolism), and HO efflux pumps [...] Read more.
We conducted a retrospective analysis of GRP94 immunohistochemical (IHC) staining, an ER stress protein, on large B-cell lymphoma (LBCL) cells, intracellular p53, and 15 factors involved in the metabolism of the CHOP regimen: AKR1C3 (HO metabolism), CYP3A4 (CHOP metabolism), and HO efflux pumps (MDR1 and MRP1). The study subjects were 42 patients with LBCL at our hospital. The IHC staining used antibodies against the 17 factors. The odds ratios by logistic regression analysis used a dichotomous variable of CR and non-CR/relapse were statistically significant for MDR1, MRP1, and AKR1C3. The overall survival (OS) after R-CHOP was compared by the log-rank test. The four groups showed that Very good (5-year OS, 100%) consisted of four patients who showed negative IHC staining for both GRP94 and CYP3A4. Very poor (1-year OS, 0%) consisted of three patients who showed positive results in IHC for both GRP94 and CYP3A4. The remaining 35 patients comprised two subgroups: Good (5-year OS 60–80%): 15 patients who showed negative staining for both MDR1 and AKR1C3 and Poor (5-year OS, 10–20%): 20 patients who showed positive staining for either MDR, AKR1C3, MRP1, or p53. The Histological Prognostic Index (HPI) (the four groups: Very poor, Poor, Good, and Very good) is a breakthrough method for stratifying patients based on the factors involved in the development of treatment resistance. Full article
(This article belongs to the Special Issue Hematological Neoplasms: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop